Search results
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoAffimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company’ ...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 4 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...
Calliditas Q1 report, January - March 2024
FOX 59 Indianapolis· 4 days agoNet sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...
Benzinga· 4 days agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
NBC 17 Raleigh· 6 days agoKS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A ...
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Morningstar· 3 days agoZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks· 4 days agoFree Report) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of myasthenia gravis ...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks· 4 days agoBiogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks· 5 days agoFree Report) announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) clinical program following a review of the phase II dose exploration study data. Shares ...